{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:03:52Z","timestamp":1790201032061,"version":"4.1.0"},"reference-count":463,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003549","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","award":["FK 128751"],"award-info":[{"award-number":["FK 128751"]}],"id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003549","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","award":["K 138518"],"award-info":[{"award-number":["K 138518"]}],"id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"National Research Development and Innovation Office","doi-asserted-by":"publisher","award":["KDP-2021"],"award-info":[{"award-number":["KDP-2021"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.bcp.2023.115448","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T18:06:26Z","timestamp":1675879586000},"page":"115448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Fluorescence-based methods for studying activity and drug-drug interactions of hepatic solute carrier and ATP binding cassette proteins involved in ADME-Tox"],"prefix":"10.1016","volume":"209","author":[{"given":"Csilla","family":"\u00d6zvegy-Laczka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Ungv\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Bakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0005","doi-asserted-by":"crossref","first-page":"G157","DOI":"10.1152\/ajpgi.00004.2017","article-title":"The liver in regulation of iron homeostasis","volume":"313","author":"Rishi","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"Suppl 7","key":"10.1016\/j.bcp.2023.115448_b0010","first-page":"S23","article-title":"Importance of hepatic transporters in clinical disposition of drugs and their metabolites","volume":"56","author":"Patel","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd2438","article-title":"Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?","volume":"7","author":"Dobson","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2023.115448_b0020","doi-asserted-by":"crossref","unstructured":"J.H.B. Keogh, C. Rynn, B. Stiegerd, G. Nicholls, Membrane transporters: fundamentals, function and their role in ADME. Drug Transporters:. 1996;olume 1: Role and Importance in ADME and Drug Development, pp. 1\u201356.","DOI":"10.1039\/9781782623793-00001"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0025","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/03602532.2014.882353","article-title":"Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism","volume":"46","author":"Doring","year":"2014","journal-title":"Drug Metab. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0035","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cpt.1112","article-title":"Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance","volume":"104","author":"Zamek-Gliszczynski","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2023.115448_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.04.018","article-title":"Drugs and hepatic transporters: a review","volume":"154","author":"Jetter","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2023.115448_b0045","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.121.000450","article-title":"Role and regulation of hepatobiliary ATP-Binding Cassete (ABC) transporters during chemical-induced liver injury","author":"Ghanem","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2023.115448_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107542","article-title":"Novel insights into the organic solute transporter alpha\/beta, OSTalpha\/beta: from the bench to the bedside","volume":"211","author":"Beaudoin","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2023.115448_b0055","unstructured":"Administration USFaD. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, 2017. <http:\/\/wwwfdagov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664htm#major>."},{"key":"10.1016\/j.bcp.2023.115448_b0060","unstructured":"https:\/\/www.ema.europa.eu\/en\/investigation-drug-interactions."},{"issue":"Suppl 7","key":"10.1016\/j.bcp.2023.115448_b0065","first-page":"S11","article-title":"Role of hepatic drug transporters in drug development","volume":"56","author":"Liu","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b0070","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1517\/17425255.2015.1053462","article-title":"Nature and uses of fluorescent dyes for drug transporter studies","volume":"11","author":"Fardel","year":"2015","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0075","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/dmd.114.062174","article-title":"Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design","volume":"43","author":"Lee","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2023.115448_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-981-13-7647-4_2","article-title":"ABC family transporters","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bcp.2023.115448_b0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-981-13-7647-4_3","article-title":"SLC family transporters","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b0090","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/humu.24418","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"43","author":"Dean","year":"2022","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0095","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.febslet.2005.11.040","article-title":"Membrane topology of human ABC proteins","volume":"580","author":"Tusnady","year":"2006","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/14728222.2016.1102889","article-title":"Recent advances in the exploration of the bile salt export pump (BSEP\/ABCB11) function","volume":"20","author":"Telbisz","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0105","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.febslet.2005.12.060","article-title":"The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research","volume":"580","author":"Gottesman","year":"2006","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"BBA"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0115","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0005-2736(73)90191-0","article-title":"Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells","volume":"323","author":"Dano","year":"1973","journal-title":"BBA"},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b0120","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0169-409X(02)00064-9","article-title":"The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans","volume":"54","author":"Fromm","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2710.2003.00487.x","article-title":"Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors","volume":"28","author":"Wang","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.bcp.2023.115448_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.576559","article-title":"P-glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers","volume":"10","author":"Seelig","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2023.115448_b0135","doi-asserted-by":"crossref","unstructured":"K. Ueda, C. Cardarelli, M.M. Gottesman, I. Pastan, Expression of a full-length cDNA for the human \u201cMDR1\u201d gene confers resistance to colchicine, doxorubicin, and vinblastine, Proc. Natl. Acad. Sci. U.S.A. 84(9) (1987) 3004\u20133008.","DOI":"10.1073\/pnas.84.9.3004"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0140","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood.V94.3.1046.415k03_1046_1056","article-title":"Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia","volume":"94","author":"Legrand","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0145","first-page":"1385","article-title":"Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123","volume":"78","author":"Ludescher","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ab.2013.02.018","article-title":"Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters","volume":"437","author":"Strouse","year":"2013","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/108705710200700105","article-title":"Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein","volume":"7","author":"Sarver","year":"2002","journal-title":"J. Biomol. Screen."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cyto.a.22038","article-title":"DyeCycle Violet used for side population detection is a substrate of P-glycoprotein","volume":"81","author":"Boesch","year":"2012","journal-title":"Cytometry A"},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b0165","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cyto.a.22931","article-title":"Application of fluorescent dye substrates for functional characterization of ABC multidrug transporters at a single cell level","volume":"89","author":"Nerada","year":"2016","journal-title":"Cytometry A"},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b0170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/dmd.119.087734","article-title":"Synthesis and characterization of bodipy-FL-cyclosporine a as a substrate for multidrug resistance-linked P-glycoprotein (ABCB1)","volume":"47","author":"Sajid","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"21","key":"10.1016\/j.bcp.2023.115448_b0175","first-page":"7763","article-title":"P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells","volume":"61","author":"Chen","year":"2001","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.bcp.2023.115448_b0180","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1021\/acs.biochem.6b01245","article-title":"Differential coupling of binding, ATP hydrolysis, and transport of fluorescent probes with P-glycoprotein in lipid nanodiscs","volume":"56","author":"Li","year":"2017","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0185","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0005-2736(94)90190-2","article-title":"Calcein accumulation as a fluorometric functional assay of the multidrug transporter","volume":"1191","author":"Hollo","year":"1994","journal-title":"BBA"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2023.115448_b0190","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-5793(96)00237-2","article-title":"Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells","volume":"383","author":"Hollo","year":"1996","journal-title":"FEBS Lett."},{"issue":"29","key":"10.1016\/j.bcp.2023.115448_b0195","doi-asserted-by":"crossref","first-page":"21493","DOI":"10.1016\/S0021-9258(20)80566-3","article-title":"Fluorescent cellular indicators are extruded by the multidrug resistance protein","volume":"268","author":"Homolya","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b0200","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/sj.leu.2400658","article-title":"Monoclonal antibodies specific for P-glycoprotein","volume":"11","author":"Okochi","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2023.115448_b0205","doi-asserted-by":"crossref","unstructured":"E.B. Mechetner, I.B. Roninson, Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody, Proc. Natl. Acad. Sci. U.S.A. 89(13) (1992) 5824\u20135828.","DOI":"10.1073\/pnas.89.13.5824"},{"key":"10.1016\/j.bcp.2023.115448_b0210","doi-asserted-by":"crossref","unstructured":"H. Hamada, T. Tsuruo, Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies, Proc. Natl. Acad. Sci. U.S.A. 83(20) (1986) 7785\u20137789.","DOI":"10.1073\/pnas.83.20.7785"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0215","first-page":"310","article-title":"Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein","volume":"53","author":"Arceci","year":"1993","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0220","doi-asserted-by":"crossref","first-page":"12716","DOI":"10.1038\/s41598-018-30984-8","article-title":"Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein","volume":"8","author":"Vahedi","year":"2018","journal-title":"Sci. Rep."},{"issue":"45","key":"10.1016\/j.bcp.2023.115448_b0225","doi-asserted-by":"crossref","first-page":"39489","DOI":"10.1074\/jbc.M111.284554","article-title":"Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2","volume":"286","author":"Ritchie","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0230","first-page":"415","article-title":"Conformational heterogeneity of P-glycoprotein","volume":"24","author":"Goda","year":"2000","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.bcp.2023.115448_b0235","doi-asserted-by":"crossref","first-page":"24810","DOI":"10.1038\/srep24810","article-title":"A single active catalytic site is sufficient to promote transport in P-glycoprotein","volume":"6","author":"Barsony","year":"2016","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.bcp.2023.115448_b0240","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1074\/jbc.RA119.012042","article-title":"In vivo FRET analyses reveal a role of ATP hydrolysis-associated conformational changes in human P-glycoprotein","volume":"295","author":"Futamata","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b0245","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11095-011-0478-6","article-title":"Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques","volume":"28","author":"On","year":"2011","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0250","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jneumeth.2013.07.001","article-title":"Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood-brain barrier","volume":"219","author":"Mittapalli","year":"2013","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcph.200","article-title":"Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity","volume":"54","author":"Nader","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0260","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/gast.2001.21176","article-title":"Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver","volume":"120","author":"Kullak-Ublick","year":"2001","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.bcp.2023.115448_b0265","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","article-title":"The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver","volume":"273","author":"Gerloff","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0270","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1389200220666190426152830","article-title":"The role of the sodium-taurocholate co-transporting polypeptide (NTCP) and bile salt export pump (BSEP) in related liver disease","volume":"20","author":"Lu","year":"2019","journal-title":"Curr. Drug Metab."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0275","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clinre.2012.06.006","article-title":"The bile salt export pump (BSEP) in health and disease","volume":"36","author":"Kubitz","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0280","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bax023","article-title":"ABCMdb reloaded: updates on mutations in ATP binding cassette proteins","volume":"2017","author":"Tordai","year":"2017","journal-title":"Database (Oxford)"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0285","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.21359","article-title":"Hepatobiliary transporters and drug-induced cholestasis","volume":"44","author":"Pauli-Magnus","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0290","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1038\/s41467-022-29931-z","article-title":"GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements","volume":"13","author":"Dixon","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0295","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12887-020-02201-x","article-title":"Histological demonstration of BSEP\/ABCB11 inhibition in transient neonatal cholestasis: a case report","volume":"20","author":"Baghdasaryan","year":"2020","journal-title":"BMC Pediatr."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b0300","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1111\/liv.14642","article-title":"ABCB11 deficiency presenting as transient neonatal cholestasis: correlation with genotypes and BSEP expression","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.fpc.0000230418.28091.76","article-title":"Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury","volume":"17","author":"Lang","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0310","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/jps.23933","article-title":"Confocal imaging with a fluorescent bile acid analogue closely mimicking hepatic taurocholate disposition","volume":"103","author":"De Bruyn","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b0315","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.105.008748","article-title":"Inhibition of bile acid transport across Na+\/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs","volume":"34","author":"Mita","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0320","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/aivt.2015.0014","article-title":"High-content imaging in human and rat hepatocytes using the fluorescent Dyes CLF and CMFDA is not specific enough to assess BSEP\/Bsep and\/or MRP2\/Mrp2 inhibition by cholestatic drugs","volume":"1","author":"Qiu","year":"2015","journal-title":"Appl. In Vitro Toxicol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0325","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2133\/dmpk.25.214","article-title":"Measurement of bile salt export pump transport activities using a fluorescent bile acid derivative","volume":"25","author":"Yamaguchi","year":"2010","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0330","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/toxsci\/kfv159","article-title":"Quantification of drug-induced inhibition of canalicular cholyl-l-lysyl-fluorescein excretion from hepatocytes by high content cell imaging","volume":"148","author":"Barber","year":"2015","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0335","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/jpet.110.166991","article-title":"Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein","volume":"334","author":"de Waart","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2023.115448_b0340","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13375","article-title":"Differential effects of metformin-mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: a randomized controlled trial","author":"Metry","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0345","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade","volume":"370","author":"Chen","year":"2016","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0350","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","article-title":"The apical conjugate efflux pump ABCC2 (MRP2)","volume":"453","author":"Nies","year":"2007","journal-title":"Pflugers Arch."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0355","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/liv.14260","article-title":"Genetic contribution of ABCC2 to Dubin-Johnson syndrome and inherited cholestatic disorders","volume":"40","author":"Corpechot","year":"2020","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0360","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.510290404","article-title":"Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane","volume":"29","author":"Konig","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0365","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/tpj.2012.37","article-title":"Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy","volume":"13","author":"Simon","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0370","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-019-02775-1","article-title":"ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects","volume":"76","author":"Cao","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b0375","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.fpc.0000230422.50962.91","article-title":"Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics","volume":"16","author":"Niemi","year":"2006","journal-title":"Pharmacogen. Genom."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0380","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0385","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jhep.2007.08.015","article-title":"Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy","volume":"48","author":"Sookoian","year":"2008","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0390","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1087057108316702","article-title":"Characterization of 5(6)-carboxy-2',7'-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4","volume":"13","author":"Heredi-Szabo","year":"2008","journal-title":"J. Biomol. Screen."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0395","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejpb.2010.03.008","article-title":"Development of a fluorescence-based assay for drug interactions with human Multidrug Resistance Related Protein (MRP2; ABCC2) in MDCKII-MRP2 membrane vesicles","volume":"75","author":"Lechner","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b0400","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1097\/01.ASN.0000094083.82845.FA","article-title":"Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR-) rats","volume":"14","author":"Masereeuw","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2023.115448_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105395","article-title":"Fluorescent probes for the dual investigation of MRP2 and OATP1B1 function and drug interactions","volume":"151","author":"Szekely","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0410","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/labinvest.3780411","article-title":"Tissue distribution and induction of human multidrug resistant protein 3","volume":"82","author":"Scheffer","year":"2002","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bcp.2023.115448_b0415","doi-asserted-by":"crossref","unstructured":"Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(12):6914-9.","DOI":"10.1073\/pnas.96.12.6914"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0420","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","article-title":"Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis","volume":"38","author":"Zollner","year":"2003","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0425","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.24801","volume":"55","author":"Chai","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0430","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/dmd.114.062703","article-title":"Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis","volume":"43","author":"Canet","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0435","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.66","article-title":"Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis","volume":"97","author":"Ferslew","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b0440","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/jcph.1592","article-title":"Influence of MRP3 genetics and hepatic expression ontogeny for morphine disposition in neonatal and pediatric patients","volume":"60","author":"Hahn","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0445","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/tpj.2011.17","article-title":"Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia","volume":"12","author":"Ansari","year":"2012","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0450","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.102.044107","article-title":"Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver","volume":"304","author":"Zamek-Gliszczynski","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"17","key":"10.1016\/j.bcp.2023.115448_b0455","first-page":"4779","article-title":"Transport of amphipathic anions by human multidrug resistance protein 3","volume":"60","author":"Zeng","year":"2000","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0460","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13046-019-1308-7","article-title":"Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer","volume":"38","author":"Adamska","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0465","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.3390\/ijms13066757","article-title":"Effects of 3beta-acethyl tormentic acid (3ATA) on ABCC proteins activity","volume":"13","author":"Rocha Gda","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0470","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.106.012765","article-title":"Inhibition of MRP1\/ABCC1, MRP2\/ABCC2, and MRP3\/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors","volume":"35","author":"Weiss","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"49","key":"10.1016\/j.bcp.2023.115448_b0475","doi-asserted-by":"crossref","first-page":"46400","DOI":"10.1074\/jbc.M107041200","article-title":"Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3)","volume":"276","author":"Zelcer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115448_b0480","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejps.2017.02.011","article-title":"Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay","volume":"103","author":"Ali","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2023.115448_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.06.015","article-title":"Multidrug resistance-associated protein 4 in pharmacology: overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics","volume":"231","author":"Berthier","year":"2019","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0490","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/hep.20682","article-title":"Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis","volume":"41","author":"Keitel","year":"2005","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b0495","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1478-3231.2007.01506.x","article-title":"Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis","volume":"27","author":"Zollner","year":"2007","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0500","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1734-1140(12)70888-5","article-title":"Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1","volume":"64","author":"Kurzawski","year":"2012","journal-title":"Pharmacol. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0505","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/dmd.113.054304","article-title":"Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4","volume":"42","author":"Kock","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0510","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1081\/DMR-200047984","article-title":"Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5)","volume":"37","author":"Ritter","year":"2005","journal-title":"Drug Metab Rev."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b0515","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/hiv.12072","article-title":"Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration","volume":"14","author":"Bickel","year":"2013","journal-title":"HIV Med."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0520","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FPC.0b013e32835c3b24","article-title":"Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia","volume":"23","author":"Lopez-Lopez","year":"2013","journal-title":"Pharmacogen. Genom."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0525","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41397-021-00235-7","article-title":"ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment","volume":"21","author":"Cheli","year":"2021","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0530","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1128\/AAC.04930-14","article-title":"Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients","volume":"59","author":"Rungtivasuwan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b0535","doi-asserted-by":"crossref","first-page":"e0205175","DOI":"10.1371\/journal.pone.0205175","article-title":"Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening","volume":"13","author":"Chen","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2014.05.023","article-title":"High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)","volume":"91","author":"Cheung","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0545","doi-asserted-by":"crossref","first-page":"R2382","DOI":"10.1152\/ajpregu.00029.2007","article-title":"Transport of a fluorescent cAMP analog in teleost proximal tubules","volume":"293","author":"Reichel","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.bcp.2023.115448_b0550","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4236\/ajmb.2020.103013","article-title":"A fluorescent cell-based technique for monitoring efflux of MRP4","volume":"10","author":"Monsi","year":"2020","journal-title":"Am. J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0555","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1357-2725(03)00236-X","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4) mediates efflux of bimane-glutathione","volume":"36","author":"Bai","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0560","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ijc.10100","article-title":"Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization","volume":"97","author":"Kage","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0565","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/bbrc.2001.5130","article-title":"Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells","volume":"285","author":"Ozvegy","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"23","key":"10.1016\/j.bcp.2023.115448_b0570","first-page":"5337","article-title":"A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance","volume":"58","author":"Allikmets","year":"1998","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/j.bcp.2023.115448_b0575","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0580","first-page":"8","article-title":"Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes","volume":"59","author":"Miyake","year":"1999","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.bcp.2023.115448_b0585","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1096\/fj.02-1131fje","article-title":"The expression and functional characterization of ABCG2 in brain endothelial cells and vessels","volume":"17","author":"Zhang","year":"2003","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b0590","first-page":"3458","article-title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues","volume":"61","author":"Maliepaard","year":"2001","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b0595","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1476-5381.2010.01177.x","article-title":"The ABCG family of membrane-associated transporters: you don't have to be big to be mighty","volume":"164","author":"Kerr","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0600","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng.1075","article-title":"ABCG2 null alleles define the Jr(a-) blood group phenotype","volume":"44","author":"Zelinski","year":"2012","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0605","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ng.1070","article-title":"Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior","volume":"44","author":"Saison","year":"2012","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0610","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s11095-008-9537-z","article-title":"BCRP\/ABCG2 in the placenta: expression, function and regulation","volume":"25","author":"Mao","year":"2008","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0615","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1124\/jpet.105.085589","volume":"314","author":"Matsushima","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0620","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1124\/dmd.113.055731","article-title":"Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites","volume":"42","author":"Telbisz","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2023.115448_b0625","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drup.2005.02.002","article-title":"Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters","volume":"8","author":"Ozvegy-Laczka","year":"2005","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0630","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2013an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0635","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/03602532.2014.942037","article-title":"Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2)","volume":"46","author":"Szafraniec","year":"2014","journal-title":"Drug Metab. Rev."},{"issue":"23","key":"10.1016\/j.bcp.2023.115448_b0640","doi-asserted-by":"crossref","first-page":"24218","DOI":"10.1074\/jbc.M313599200","article-title":"The stem cell marker Bcrp\/ABCG2 enhances hypoxic cell survival through interactions with heme","volume":"279","author":"Krishnamurthy","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"25","key":"10.1016\/j.bcp.2023.115448_b0645","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.1073\/pnas.0901249106","article-title":"Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout","volume":"106","author":"Woodward","year":"2009","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0650","first-page":"47","article-title":"Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein","volume":"60","author":"Rabindran","year":"2000","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0655","first-page":"417","article-title":"Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C","volume":"1","author":"Allen","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.bcp.2023.115448_b0660","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1021\/jm401649j","article-title":"Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2","volume":"56","author":"Winter","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115448_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113017","article-title":"Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2","volume":"211","author":"Guragossian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115448_b0670","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of human ABCG2: from technical background to recent updates with clinical implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"19","key":"10.1016\/j.bcp.2023.115448_b0675","doi-asserted-by":"crossref","first-page":"14311","DOI":"10.1021\/acs.jmedchem.1c00779","article-title":"Flavonoid monomers as potent, nontoxic, and selective modulators of the breast cancer resistance protein (ABCG2)","volume":"64","author":"Wong","year":"2021","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2023.115448_b0680","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1124\/dmd.118.083030","article-title":"Polymorphisms of the multidrug pump ABCG2: a systematic review of their effect on protein expression, function, and drug pharmacokinetics","volume":"46","author":"Heyes","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0685","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1038\/s41598-018-25695-z","article-title":"Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane protein expression","volume":"8","author":"Zambo","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0690","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00280-004-0931-x","article-title":"Single nucleotide polymorphisms modify the transporter activity of ABCG2","volume":"56","author":"Morisaki","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115448_b0695","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2017.10.004","article-title":"BCRP\/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications","volume":"147","author":"Hira","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b0700","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","article-title":"The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype","volume":"7","author":"Zhou","year":"2001","journal-title":"Nat. Med."},{"issue":"38","key":"10.1016\/j.bcp.2023.115448_b0705","doi-asserted-by":"crossref","first-page":"26059","DOI":"10.1074\/jbc.M803230200","article-title":"Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter","volume":"283","author":"Ozvegy-Laczka","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0710","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1074\/jbc.M411338200","article-title":"Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface","volume":"280","author":"Ozvegy-Laczka","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2023.115448_b0715","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejps.2011.10.021","article-title":"Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter","volume":"45","author":"Telbisz","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b0720","doi-asserted-by":"crossref","first-page":"e48423","DOI":"10.1371\/journal.pone.0048423","article-title":"Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations","volume":"7","author":"Kasza","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2023.115448_b0725","article-title":"Noninvasive evaluation of multidrug resistance via imaging of ABCG2\/BCRP multidrug transporter in lung cancer xenograft models","author":"Li","year":"2022","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b0730","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/dmd.121.000430","article-title":"Comparative hepatic and intestinal efflux transport of statins","volume":"49","author":"Deng","year":"2021","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0735","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1124\/mol.115.102079","article-title":"Generation and characterization of a breast cancer resistance protein humanized mouse model","volume":"89","author":"Dallas","year":"2016","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0740","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/hep.510260613","article-title":"Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat","volume":"26","author":"Jager","year":"1997","journal-title":"Hepatology"},{"issue":"Pt 11","key":"10.1016\/j.bcp.2023.115448_b0745","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1242\/jcs.113.11.2011","article-title":"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)","volume":"113","author":"Litman","year":"2000","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0750","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cpt.2627","article-title":"New and emerging research on solute carrier and ATP binding cassette transporters in drug discovery and development: outlook from the international transporter consortium","volume":"112","author":"Giacomini","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0755","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0005-2736(01)00308-X","article-title":"A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)","volume":"1512","author":"Robey","year":"2001","journal-title":"BBA"},{"issue":"24","key":"10.1016\/j.bcp.2023.115448_b0760","doi-asserted-by":"crossref","first-page":"15649","DOI":"10.1073\/pnas.202607599","article-title":"The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria","volume":"99","author":"Jonker","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"50","key":"10.1016\/j.bcp.2023.115448_b0765","doi-asserted-by":"crossref","first-page":"47980","DOI":"10.1074\/jbc.M207857200","article-title":"Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation","volume":"277","author":"Ozvegy","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0770","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/adt.2013.521","article-title":"A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells","volume":"12","author":"Antczak","year":"2014","journal-title":"Assay Drug Dev. Technol."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b0775","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6601370","article-title":"Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity","volume":"89","author":"Robey","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b0780","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s11095-017-2127-1","article-title":"Transmembrane domain single-nucleotide polymorphisms impair expression and transport activity of ABC transporter ABCG2","volume":"34","author":"Sjostedt","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2023.115448_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113865","article-title":"Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells","volume":"175","author":"Kovacsics","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0790","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tips.2016.11.008","article-title":"Classification systems of secondary active transporters","volume":"38","author":"Perland","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2023.115448_b0795","doi-asserted-by":"crossref","DOI":"10.3390\/biom10121611","article-title":"Sequence features of mitochondrial transporter protein families","volume":"10","author":"Gyimesi","year":"2020","journal-title":"Biomolecules"},{"issue":"2\u20133","key":"10.1016\/j.bcp.2023.115448_b0800","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mam.2012.12.009","article-title":"The ABCs of membrane transporters in health and disease (SLC series): introduction","volume":"34","author":"Hediger","year":"2013","journal-title":"Mol. Aspects Med."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0805","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0810","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/mol.116.105544","article-title":"Contribution of organic anion-transporting polypeptides 1A\/1B to doxorubicin uptake and clearance","volume":"91","author":"Lee","year":"2017","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0815","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","article-title":"Organic anion transporting polypeptides of the OATP\/ SLC21 family: phylogenetic classification as OATP\/ SLCO superfamily, new nomenclature and molecular\/functional properties","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.bcp.2023.115448_b0820","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bcp.2017.12.012","article-title":"LST-3TM12 is a member of the OATP1B family and a functional transporter","volume":"148","author":"Malagnino","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"3\u20135","key":"10.1016\/j.bcp.2023.115448_b0825","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jsbmb.2009.04.003","article-title":"Transcriptional control of human organic anion transporting polypeptide 2B1 gene","volume":"115","author":"Pomari","year":"2009","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0830","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/mol.112.083618","article-title":"Transport function and transcriptional regulation of a liver-enriched human organic anion transporting polypeptide 2B1 transcriptional start site variant","volume":"83","author":"Knauer","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0835","doi-asserted-by":"crossref","first-page":"C795","DOI":"10.1152\/ajpcell.00597.2005","article-title":"Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain","volume":"292","author":"Huber","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2023.115448_b0840","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.958023","article-title":"Cloning and characterization of a novel functional organic anion transporting polypeptide 3A1 isoform highly expressed in the human brain and testis","volume":"13","author":"Bakos","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0845","doi-asserted-by":"crossref","first-page":"G156","DOI":"10.1152\/ajpgi.2000.278.1.G156","article-title":"A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane","volume":"278","author":"Konig","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b0850","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1053\/gast.2001.24804","article-title":"LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers","volume":"120","author":"Abe","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0855","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/db13-1005","article-title":"OATP1B3 is expressed in pancreatic beta-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide","volume":"63","author":"Meyer Zu Schwabedissen","year":"2014","journal-title":"Diabetes."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0860","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2174\/1389200216666150812142715","article-title":"Cancer-type organic anion transporting polypeptide 1B3: current knowledge of the gene structure, expression profile, functional implications and future perspectives","volume":"16","author":"Furihata","year":"2015","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0865","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/mp3005353","article-title":"A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells","volume":"10","author":"Thakkar","year":"2013","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b0870","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1007\/s11095-013-1117-1","article-title":"Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines","volume":"30","author":"Imai","year":"2013","journal-title":"Pharm. Res."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2023.115448_b0875","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The SLCO (former SLC21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol. Aspects Med."},{"issue":"14","key":"10.1016\/j.bcp.2023.115448_b0880","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147947","article-title":"Protein abundance of drug transporters in human hepatitis C livers","volume":"23","author":"Drozdzik","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b0885","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/liv.14452","article-title":"Cell-type-resolved proteomic analysis of the human liver","volume":"40","author":"Olander","year":"2020","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b0890","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1021\/acs.jproteome.5b00334","article-title":"Comparative proteomic analysis of human liver tissue and isolated hepatocytes with a focus on proteins determining drug exposure","volume":"14","author":"Vildhede","year":"2015","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(02)00633-8","article-title":"The superfamily of organic anion transporting polypeptides","volume":"1609","author":"Hagenbuch","year":"2003","journal-title":"BBA"},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b0900","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12080755","article-title":"Prediction of drug-induced hyperbilirubinemia by in vitro testing","volume":"12","author":"Tatrai","year":"2020","journal-title":"Pharmaceutics."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0905","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2023.115448_b0910","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-12-394316-3.00004-1","article-title":"The SLC10 carrier family: transport functions and molecular structure","volume":"70","author":"Doring","year":"2012","journal-title":"Curr. Top. Membr."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0915","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/17425255.2017.1253679","article-title":"The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions","volume":"13","author":"Kovacsics","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"38","key":"10.1016\/j.bcp.2023.115448_b0920","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.M103792200","article-title":"Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans","volume":"276","author":"Tirona","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b0925","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.fpc.0000114750.08559.32","article-title":"High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)","volume":"14","author":"Niemi","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0930","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/jpet.102.041921","article-title":"Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A","volume":"304","author":"Shitara","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b0935","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b0940","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1248\/bpb.b14-00767","article-title":"Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs","volume":"38","author":"Maeda","year":"2015","journal-title":"Biol. Pharm. Bull."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b0945","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.xphs.2017.04.031","article-title":"Imaging probes and modalities for the Study of Solute Carrier O (SLCO)-transport function in vivo","volume":"106","author":"Marie","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0950","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cpt.888","article-title":"Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography","volume":"104","author":"Bauer","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b0955","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/dmd.110.032862","article-title":"Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters","volume":"38","author":"Leonhardt","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0960","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jhep.2010.07.047","article-title":"Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green","volume":"54","author":"de Graaf","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2023.115448_b0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1875397301004010001","article-title":"Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3","volume":"4","author":"Gui","year":"2010","journal-title":"Curr Chem Genomics."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b0970","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1002\/jps.22694","article-title":"Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3","volume":"100","author":"De Bruyn","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b0975","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1248\/bpb.34.389","article-title":"Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes","volume":"34","author":"Yamaguchi","year":"2011","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b0980","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bcp.2015.09.015","article-title":"Functional expression of the 11 human Organic Anion Transporting Polypeptides in insect cells reveals that sodium fluorescein is a general OATP substrate","volume":"98","author":"Patik","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b0985","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/s41598-018-20815-1","article-title":"Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1\/1B3 and 2B1","volume":"8","author":"Patik","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b0990","doi-asserted-by":"crossref","first-page":"e21863","DOI":"10.1096\/fj.202100648R","article-title":"8-acetoxy-trisulfopyrene as the first activatable fluorogenic probe for add-and-read assessment of Organic anion-transporting polypeptides, OATP1B1, OATP1B3, and OATP2B1","volume":"35","author":"Ungvari","year":"2021","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b0995","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s13318-020-00634-4","article-title":"Potential risk of food-drug interactions: citrus polymethoxyflavones and flavanones as inhibitors of the Organic Anion Transporting Polypeptides (OATP) 1B1, 1B3, and 2B1","volume":"45","author":"Bajraktari-Sylejmani","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.bcp.2023.115448_b1000","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/febs.15156","article-title":"A novel fluorescence-based functional assay for human OATP1A2 and OATP1C1 identifies interaction between third-generation P-gp inhibitors and OATP1A2","volume":"287","author":"Bakos","year":"2020","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/acs.molpharmaceut.5b00664","article-title":"Investigation of Fluorescein derivatives as substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 to develop sensitive fluorescence-based OATP1B1 inhibition assays","volume":"13","author":"Izumi","year":"2016","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11095-020-02831-x","article-title":"Investigation of fluorescent substrates and substrate-dependent interactions of a drug transporter organic anion transporting polypeptide 2B1 (OATP2B1)","volume":"37","author":"Kawasaki","year":"2020","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","article-title":"Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1","volume":"40","author":"Annaert","year":"2010","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1020","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.120.000449","article-title":"Characterization of novel fluorescent bile salt derivatives for studying human bile salt and organic anion transporters","volume":"377","author":"Leuenberger","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1194\/jlr.M500532-JLR200","article-title":"Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3","volume":"47","author":"Yamaguchi","year":"2006","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1035","first-page":"G157","article-title":"Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter","volume":"274","author":"Craddock","year":"1998","journal-title":"Am. J. Phys. Anthropol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b1040","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1002\/jps.22548","article-title":"Characterization of human OCT1-mediated transport of DAPI as a fluorescent probe substrate","volume":"100","author":"Yasujima","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b1045","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0006-2952(95)00045-2","article-title":"Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells","volume":"49","author":"Fardel","year":"1995","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1050","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1124\/mol.60.5.934","article-title":"Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2","volume":"60","author":"Cui","year":"2001","journal-title":"Mol. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b1055","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1021\/jm7015683","article-title":"Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2)","volume":"51","author":"Pedersen","year":"2008","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bcp.2023.115448_b1060","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1021\/jm8003152","article-title":"Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1","volume":"51","author":"Ahlin","year":"2008","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b1065","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115448_b1070","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jcim.1c01460","article-title":"Identifying novel inhibitors for hepatic organic anion transporting polypeptides by machine learning-based virtual screening","author":"Tuerkova","year":"2022","journal-title":"J. Chem. Inf. Model."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b1075","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bcp.2010.08.008","article-title":"Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1","volume":"80","author":"Mandery","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2023.115448_b1080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2012.02.014","article-title":"Inhibition of hepatic uptake transporters by flavonoids","volume":"46","author":"Mandery","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2023.115448_b1085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/B978-0-12-800223-0.00005-0","article-title":"Organic anion-transporting polypeptides","volume":"73","author":"Stieger","year":"2014","journal-title":"Curr. Top. Membr."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1090","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cpt.749","article-title":"Endogenous probes for drug transporters: balancing vision with reality","volume":"103","author":"Rodrigues","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2023.115448_b1095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-642-14541-4_5","article-title":"The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation","volume":"201","author":"Stieger","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115448_b1100","first-page":"3","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","author":"Yan","year":"2012","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b1105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/bdd.1861","article-title":"Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin","volume":"34","author":"Bi","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b1110","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1021\/mp3001815","article-title":"Pharmaceutical excipients influence the function of human uptake transporting proteins","volume":"9","author":"Engel","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2023.115448_b1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2014.09.005","article-title":"Quantitative NTCP pharmacophore and lack of association between DILI and NTCP inhibition","volume":"66","author":"Dong","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhepr.2019.07.006","article-title":"Mechanistic insights into the inhibition of NTCP by myrcludex B","volume":"1","author":"Donkers","year":"2019","journal-title":"JHEP Rep."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3851\/IMP3206","article-title":"Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro","volume":"23","author":"Blank","year":"2018","journal-title":"Antivir. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101824","article-title":"Sodium taurocholate co-transporting polypeptide deficiency","volume":"46","author":"Schneider","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/1091581820953066","article-title":"Assessment of Statin Interactions With the Human NTCP Transporter Using a Novel Fluorescence Assay","volume":"39","author":"Wang","year":"2020","journal-title":"Int. J. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1140","doi-asserted-by":"crossref","first-page":"G60","DOI":"10.1152\/ajpgi.00035.2011","article-title":"Heterogeneous accumulation of fluorescent bile acids in primary rat hepatocytes does not correlate with their homogenous expression of ntcp","volume":"301","author":"Murray","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115448_b1145","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24122295","article-title":"Use of Indocyanine Green (ICG), a medical near infrared dye, for enhanced fluorescent imaging-comparison of organic anion transporting polypeptide 1B3 (OATP1B3) and Sodium-Taurocholate Cotransporting Polypeptide (NTCP) reporter genes","volume":"24","author":"Wu","year":"2019","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11307-019-01373-y","article-title":"Role of sodium taurocholate cotransporting polypeptide as a new reporter and drug-screening platform: implications for preventing hepatitis B virus infections","volume":"22","author":"Wu","year":"2020","journal-title":"Mol. Imag. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1155","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/hep.26012","article-title":"Monitoring bile acid transport in single living cells using a genetically encoded Forster resonance energy transfer sensor","volume":"57","author":"van der Velden","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1160","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.bmc.2016.12.008","article-title":"Design, synthesis, in vitro characterization and preliminary imaging studies on fluorinated bile acid derivatives as PET tracers to study hepatic transporters","volume":"25","author":"Testa","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1165","doi-asserted-by":"crossref","first-page":"e0173529","DOI":"10.1371\/journal.pone.0173529","article-title":"Synthesis, in vitro and in vivo evaluation of 3beta-[18F]fluorocholic acid for the detection of drug-induced cholestasis in mice","volume":"12","author":"De Lombaerde","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1170","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s11095-012-0963-6","article-title":"Design and characterization of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile Acid transporter activity","volume":"30","author":"Vivian","year":"2013","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/03602532.2019.1670204","article-title":"The human organic cation transporter OCT1 and its role as a target for drug responses","volume":"51","author":"Brosseau","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bcp.2023.115448_b1180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-642-14541-4_3","article-title":"Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy","volume":"201","author":"Nies","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115448_b1185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.662535","article-title":"Transport of drugs and endogenous compounds mediated by human OCT1: studies in single- and double-transfected cell models","volume":"12","author":"Haberkorn","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115448_b1190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.648388","article-title":"Organic cation transporter 1 an intestinal uptake transporter: fact or fiction?","volume":"12","author":"Wenzel","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115448_b1195","article-title":"Drug-drug interactions at organic cation transporter 1","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1200","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Shu","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","article-title":"Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics","volume":"83","author":"Shu","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1472-8206.2012.01071.x","article-title":"The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2","volume":"28","author":"Jouan","year":"2014","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115448_b1215","doi-asserted-by":"crossref","first-page":"20508","DOI":"10.1038\/srep20508","article-title":"The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin","volume":"6","author":"Andreev","year":"2016","journal-title":"Sci. Rep."},{"issue":"50","key":"10.1016\/j.bcp.2023.115448_b1220","doi-asserted-by":"crossref","first-page":"17923","DOI":"10.1073\/pnas.0506483102","article-title":"A human transporter protein that mediates the final excretion step for toxic organic cations","volume":"102","author":"Otsuka","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b1225","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1681\/ASN.2006030205","article-title":"Identification and functional characterization of a new human kidney-specific H+\/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2","volume":"17","author":"Masuda","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bcp.2007.04.010","article-title":"Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions\/H(+)-organic cation antiporters","volume":"74","author":"Tanihara","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115448_b1235","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bbrc.2022.01.014","article-title":"Amiloride is a suitable fluorescent substrate for the study of the drug transporter human multidrug and toxin extrusion 1 (MATE1)","volume":"592","author":"Kawasaki","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1240","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1021\/jm301302s","article-title":"Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling","volume":"56","author":"Wittwer","year":"2013","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1245","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/mol.109.056242","article-title":"Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin","volume":"75","author":"Tsuda","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1250","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/dmd.108.023911","article-title":"The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine","volume":"37","author":"Matsushima","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1255","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/dmd.109.030221","article-title":"Evaluation of 4',6-diamidino-2-phenylindole as a fluorescent probe substrate for rapid assays of the functionality of human multidrug and toxin extrusion proteins","volume":"38","author":"Yasujima","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1260","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1074\/jbc.M307938200","article-title":"Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs","volume":"279","author":"Lai","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1265","doi-asserted-by":"crossref","first-page":"G570","DOI":"10.1152\/ajpgi.00542.2007","article-title":"Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes","volume":"295","author":"Govindarajan","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcp.2023.115448_b1270","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fphar.2018.00606","article-title":"Emerging roles of nucleoside transporters","volume":"9","author":"Pastor-Anglada","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1275","doi-asserted-by":"crossref","first-page":"e16331","DOI":"10.1371\/journal.pone.0016331","article-title":"Functional role of the polymorphic 647 T\/C variant of ENT1 (SLC29A1) and its association with alcohol withdrawal seizures","volume":"6","author":"Kim","year":"2011","journal-title":"PLoS One"},{"issue":"47","key":"10.1016\/j.bcp.2023.115448_b1280","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1038\/sj.onc.1206952","article-title":"Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy","volume":"22","author":"Damaraju","year":"2003","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.bcp.2023.115448_b1285","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","volume":"275","author":"Ward","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115448_b1290","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejphar.2016.07.002","article-title":"Inhibition of human equilibrative nucleoside transporters by 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-tr iazin-2-amine","volume":"791","author":"Tang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1295","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s002100000214","article-title":"Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity","volume":"361","author":"Hammond","year":"2000","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1300","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1021\/bi0520535","article-title":"Studies of nucleoside transporters using novel autofluorescent nucleoside probes","volume":"45","author":"Zhang","year":"2006","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1305","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/bc2000758","article-title":"Design, synthesis, and evaluation of 2-diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N, N -diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein conjugate (8MDP-fluor), as a novel equilibrative nucleoside transporter probe","volume":"22","author":"Lin","year":"2011","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1310","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/dmd.116.072264","article-title":"Organic anion transporter 2: an enigmatic human solute carrier","volume":"45","author":"Shen","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1315","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.301.3.797","article-title":"Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors","volume":"301","author":"Enomoto","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1320","doi-asserted-by":"crossref","first-page":"F361","DOI":"10.1152\/ajprenal.00207.2006","article-title":"Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones","volume":"292","author":"Ljubojevic","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1325","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1006\/bbrc.2001.4774","article-title":"Isolation of a family of organic anion transporters from human liver and kidney","volume":"283","author":"Sun","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1330","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1124\/mol.107.043117","article-title":"Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP","volume":"73","author":"Cropp","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1335","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1211\/0022357055966","article-title":"Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7])","volume":"57","author":"Kobayashi","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1340","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/BJ20101904","article-title":"OAT2 catalyses efflux of glutamate and uptake of orotic acid","volume":"436","author":"Fork","year":"2011","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1345","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.21596","article-title":"Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate","volume":"45","author":"Shin","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b1350","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/00498254.2017.1384595","article-title":"In vitro studies with two human organic anion transporters: OAT2 and OAT7","volume":"48","author":"Mathialagan","year":"2018","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1355","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/tpj.2015.55","article-title":"Variability in hepatic expression of organic anion transporter 7\/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors","volume":"16","author":"Emami Riedmaier","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"25","key":"10.1016\/j.bcp.2023.115448_b1360","doi-asserted-by":"crossref","first-page":"21233","DOI":"10.1074\/jbc.M112.352245","article-title":"beta-Subunit of the Ostalpha-Ostbeta organic solute transporter is required not only for heterodimerization and trafficking but also for function","volume":"287","author":"Christian","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"30","key":"10.1016\/j.bcp.2023.115448_b1365","doi-asserted-by":"crossref","first-page":"27473","DOI":"10.1074\/jbc.M301106200","article-title":"Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter","volume":"278","author":"Seward","year":"2003","journal-title":"OSTalpha-OSTbeta. J Biol Chem."},{"issue":"16","key":"10.1016\/j.bcp.2023.115448_b1370","doi-asserted-by":"crossref","first-page":"9431","DOI":"10.1073\/pnas.161099898","article-title":"Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate","volume":"98","author":"Wang","year":"2001","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1375","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000324123","article-title":"Pleiotropic functions of the organic solute transporter Ostalpha-Ostbeta","volume":"29","author":"Ballatori","year":"2011","journal-title":"Dig. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1380","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.20961","article-title":"OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia","volume":"42","author":"Ballatori","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1385","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.29516","article-title":"Organic solute transporter-beta (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasis","volume":"68","author":"Sultan","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1390","article-title":"Differential and organ-specific functions of organic solute transporter alpha and beta in experimental cholestasis","volume":"4","author":"van de Wiel","year":"2022","journal-title":"JHEP Rep."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1395","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/toxsci\/kfaa052","article-title":"Role of organic solute transporter alpha\/beta in hepatotoxic bile acid transport and drug interactions","volume":"176","author":"Beaudoin","year":"2020","journal-title":"Toxicol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1400","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcmgh.2017.11.011","article-title":"Intestinal farnesoid X receptor activation by pharmacologic inhibition of the organic solute transporter alpha-beta","volume":"5","author":"van de Wiel","year":"2018","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2023.115448_b1405","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.physiol.64.082201.100300","article-title":"Bile salt transporters","volume":"64","author":"Meier","year":"2002","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.bcp.2023.115448_b1410","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-981-13-7647-4_6","article-title":"Roles of hepatic drug transporters in drug disposition and liver toxicity","volume":"1141","author":"Pan","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bcp.2023.115448_b1415","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-981-13-7647-4_5","volume":"1141","author":"Transporter-Mediated","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1420","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13030369","article-title":"Interaction of remdesivir with clinically relevant hepatic drug uptake transporters","volume":"13","author":"Nies","year":"2021","journal-title":"Pharmaceutics."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1425","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cpt.2236","article-title":"Drugs in COVID-19 clinical trials: predicting transporter-mediated drug-drug interactions using in vitro assays and real-world data","volume":"110","author":"Yee","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1430","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010081","article-title":"Interactions of potential Anti-COVID-19 compounds with multispecific ABC and OATP drug transporters","volume":"13","author":"Telbisz","year":"2021","journal-title":"Pharmaceutics."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1435","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1038\/s41598-021-97160-3","article-title":"Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics","volume":"11","author":"Ambrus","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2023.115448_b1440","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2019.04.003","article-title":"The mechanisms of pharmacokinetic food-drug interactions \u2013 a perspective from the UNGAP group","volume":"134","author":"Koziolek","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b1445","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/dmd.120.000085","article-title":"Effects of chrysin and its major conjugated metabolites chrysin-7-sulfate and chrysin-7-glucuronide on cytochrome P450 enzymes and on OATP, P-gp, BCRP, and MRP2 transporters","volume":"48","author":"Mohos","year":"2020","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b1450","doi-asserted-by":"crossref","DOI":"10.3390\/nu12082306","article-title":"Inhibitory effects of quercetin and its main methyl, sulfate, and glucuronic acid conjugates on cytochrome P450 enzymes, and on OATP, BCRP and MRP2 transporters","volume":"12","author":"Mohos","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.bcp.2023.115448_b1455","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113136","article-title":"Interactions of resveratrol and its metabolites (resveratrol-3-sulfate, resveratrol-3-glucuronide, and dihydroresveratrol) with serum albumin, cytochrome P450 enzymes, and OATP transporters","volume":"151","author":"Poor","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2023.115448_b1460","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119975","article-title":"Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis","volume":"291","author":"Zechner","year":"2022","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1465","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/138920021602150713114921","article-title":"Interaction of isoflavones with the BCRP\/ABCG2 drug transporter","volume":"16","author":"Bircsak","year":"2015","journal-title":"Curr. Drug Metab."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b1470","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/17425250902997967","article-title":"Dietary regulation of P-gp function and expression","volume":"5","author":"Zhang","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1475","first-page":"621","article-title":"Evaluation of the Mrp2-mediated flavonoid-drug interaction potential of quercetin in rats and in vitro models","volume":"14","author":"Oh","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b1480","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b1485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22095038","article-title":"In vitro liver toxicity testing of chemicals: a pragmatic approach","volume":"22","author":"Tabernilla","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1490","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/hep.23720","article-title":"Pharmacogenetics of drug-induced liver injury","volume":"52","author":"Russmann","year":"2010","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b1495","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2174\/138920112802273353","article-title":"Legalon(R) SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning","volume":"13","author":"Mengs","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1500","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hep.24229","article-title":"Drug-induced cholestasis","volume":"53","author":"Padda","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1505","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40264-018-0743-2","article-title":"Drug-induced liver injury: highlights of the recent literature","volume":"42","author":"Real","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.bcp.2023.115448_b1510","doi-asserted-by":"crossref","first-page":"9176937","DOI":"10.1155\/2017\/9176937","article-title":"Idiosyncratic Drug-Induced Liver Injury (IDILI): potential mechanisms and predictive assays","volume":"2017","author":"Roth","year":"2017","journal-title":"Biomed Res. Int."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1515","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/mol.110.067256","article-title":"Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3\/ABCB4","volume":"79","author":"Yoshikado","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1520","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jhep.2022.01.020","article-title":"Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity","volume":"77","author":"deGhallab","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2023.115448_b1525","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejps.2017.01.002","article-title":"Linking organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1 and OATP1B3) interaction profiles to hepatotoxicity \u2013 the hyperbilirubinemia use case","volume":"100","author":"Kotsampasakou","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1530","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/hep.29802","article-title":"Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort","volume":"69","author":"Church","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115448_b1535","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109728","article-title":"The hepatocyte export carrier inhibition assay improves the separation of hepatotoxic from non-hepatotoxic compounds","volume":"351","author":"Brecklinghaus","year":"2022","journal-title":"Chem. Biol. Interact."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b1540","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/FPC.0b013e3280ef698f","article-title":"Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants","volume":"17","author":"Ho","year":"2007","journal-title":"Pharmacogene. Genomics"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1545","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FPC.0b013e328335b02d","article-title":"HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms","volume":"20","author":"Hartkoorn","year":"2010","journal-title":"Pharmacogenet. Genom"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1550","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","article-title":"Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"23","key":"10.1016\/j.bcp.2023.115448_b1555","doi-asserted-by":"crossref","first-page":"37761","DOI":"10.18632\/oncotarget.17781","article-title":"Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115448_b1560","article-title":"A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics","author":"Lehtisalo","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1565","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cpt.2674","article-title":"Genomewide association study of simvastatin pharmacokinetics","volume":"112","author":"Mykkanen","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2023.115448_b1570","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cca.2009.04.003","article-title":"Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism","volume":"405","author":"He","year":"2009","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1575","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clpt.2005.07.005","article-title":"Cyclosporine markedly raises the plasma concentrations of repaglinide","volume":"78","author":"Kajosaari","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1580","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/clpt.2008.74","article-title":"Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism","volume":"84","author":"Kalliokoski","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1585","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1590","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/phar.1928","article-title":"Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in brazilian kidney transplant recipients","volume":"37","author":"Genvigir","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1595","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1600","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13073-016-0372-2","article-title":"Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters","volume":"8","author":"Matthaei","year":"2016","journal-title":"Genome. Med."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1605","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2014.65","article-title":"Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness","volume":"15","author":"Cusato","year":"2015","journal-title":"Pharmacogenom. J."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1610","doi-asserted-by":"crossref","first-page":"e64114","DOI":"10.1371\/journal.pone.0064114","article-title":"Pharmacogenetic study of deferasirox, an iron chelating agent","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b1615","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/00498254.2015.1130881","article-title":"Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers","volume":"46","author":"Lu","year":"2016","journal-title":"Xenobiotica"},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b1620","first-page":"775","article-title":"The effect of Na+\/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males","volume":"69","author":"Lou","year":"2014","journal-title":"Pharmazie"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1625","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41397-018-0035-3","article-title":"An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C","volume":"19","author":"Soko","year":"2019","journal-title":"Pharmacogenomics J"},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b1630","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b1635","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1124\/dmd.116.071050","article-title":"Transporter expression in liver tissue from subjects with alcoholic or hepatitis c cirrhosis quantified by targeted quantitative proteomics","volume":"44","author":"Wang","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"9\u201310","key":"10.1016\/j.bcp.2023.115448_b1640","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","article-title":"The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)","volume":"13","author":"Szakacs","year":"2008","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1645","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/clpt.2013.81","article-title":"In vitro methods to support transporter evaluation in drug discovery and development","volume":"94","author":"Brouwer","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1650","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/138920007780655423","article-title":"Evaluation of drug-transporter interactions using in vitro and in vivo models","volume":"8","author":"Xia","year":"2007","journal-title":"Curr. Drug Metab."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b1655","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1016\/S0021-9258(18)42909-2","article-title":"Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase","volume":"267","author":"Sarkadi","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1660","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0026-895X(24)26477-4","article-title":"Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions","volume":"57","author":"Bakos","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"26","key":"10.1016\/j.bcp.2023.115448_b1665","doi-asserted-by":"crossref","first-page":"23529","DOI":"10.1074\/jbc.M303515200","article-title":"Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions","volume":"278","author":"Bodo","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1670","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1086\/689592","article-title":"Imaging Adenosine Triphosphate (ATP)","volume":"231","author":"Rajendran","year":"2016","journal-title":"Biol. Bull."},{"issue":"24","key":"10.1016\/j.bcp.2023.115448_b1675","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1021\/bi060308o","article-title":"The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: evidence for a conserved subdomain, the A-loop in the ATP-binding cassette","volume":"45","author":"Kim","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2023.115448_b1680","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.722889","article-title":"An overview of cell-based assay platforms for the solute carrier family of transporters","volume":"12","author":"Dvorak","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1685","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/dmd.121.000783","article-title":"Experimental and modeling evidence supporting the trans-inhibition mechanism for preincubation time-dependent, long-lasting inhibition of organic anion transporting polypeptide 1B1 by cyclosporine A","volume":"50","author":"Izumi","year":"2022","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1690","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.DMPK-11-RG-096","article-title":"Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake","volume":"27","author":"Shitara","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1695","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00204-019-02417-6","article-title":"Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen","volume":"93","author":"Windt","year":"2019","journal-title":"Arch. Toxicol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b1700","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1124\/dmd.106.009530","article-title":"Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells","volume":"34","author":"Sai","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1705","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1085\/jgp.41.2.289","article-title":"Uphill transport induced by counterflow","volume":"41","author":"Rosenberg","year":"1957","journal-title":"J. Gen. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1710","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0022-3565(25)12700-6","article-title":"Effect of endogenous and exogenous polyamines on organic cation transport in rabbit renal plasma membrane vesicles","volume":"255","author":"Sokol","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1715","doi-asserted-by":"crossref","first-page":"F56","DOI":"10.1152\/ajprenal.00486.2012","article-title":"Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2","volume":"304","author":"Harper","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115448_b1720","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.molpharmaceut.8b00631","article-title":"Establishment and validation of competitive counterflow as a method to detect substrates of the organic anion transporting polypeptide 2B1","volume":"15","author":"Schafer","year":"2018","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1725","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1021\/acs.molpharmaceut.0c00159","article-title":"OATP1A2 and OATP2B1 are interacting with dopamine-receptor agonists and antagonists","volume":"17","author":"Schafer","year":"2020","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b1730","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1074\/jbc.M109081200","article-title":"Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2\/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2\/ABCC2)","volume":"277","author":"Sasaki","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1735","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1124\/mol.105.014605","article-title":"Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells","volume":"68","author":"Kopplow","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b1740","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1124\/dmd.109.027193","article-title":"Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1\/multidrug resistance-associated protein (MRP) 2\/MRP3 and OATP1B1\/MRP2\/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4","volume":"37","author":"Hirouchi","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1745","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.xphs.2020.10.064","article-title":"Transient, tunable expression of NTCP and BSEP in MDCKII cells for kinetic delineation of the rate-determining process and inhibitory effects of rifampicin in hepatobiliary transport of taurocholate","volume":"110","author":"Ito","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1750","doi-asserted-by":"crossref","first-page":"G550","DOI":"10.1152\/ajpgi.00364.2005","article-title":"Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep","volume":"290","author":"Mita","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1755","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejps.2011.05.002","article-title":"Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes","volume":"43","author":"De Bruyn","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2023.115448_b1760","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejps.2008.06.008","article-title":"Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human","volume":"35","author":"Li","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1765","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/17425255.2013.773973","article-title":"Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity","volume":"9","author":"De Bruyn","year":"2013","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1770","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1124\/dmd.117.079236","article-title":"Sandwich-cultured hepatocytes for mechanistic understanding of hepatic disposition of parent drugs and metabolites by transporter-enzyme interplay","volume":"46","author":"Matsunaga","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2023.115448_b1775","doi-asserted-by":"crossref","unstructured":"K.M. Bircsak, C.J. Gibson, R.W. Robey, L.M. Aleksunes, Assessment of drug transporter function using fluorescent cell imaging, Curr. Protoc. Toxicol. 57 (2013) Unit 23 6.","DOI":"10.1002\/0471140856.tx2306s57"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1780","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/abio.1998.3087","article-title":"A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles","volume":"268","author":"Bebawy","year":"1999","journal-title":"Anal. Biochem."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b1785","doi-asserted-by":"crossref","first-page":"e0163886","DOI":"10.1371\/journal.pone.0163886","article-title":"The effect of albumin on MRP2 and BCRP in the vesicular transport assay","volume":"11","author":"Deng","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1790","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejpb.2005.06.001","article-title":"Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3)","volume":"62","author":"Baldes","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1795","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ab.2010.06.012","article-title":"Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3","volume":"405","author":"Bednarczyk","year":"2010","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1800","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1054\/bjoc.2000.1260","article-title":"Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport","volume":"83","author":"Evers","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b1805","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/00498254.2011.587033","article-title":"Calcein assay: a high-throughput method to assess P-gp inhibition","volume":"41","author":"Glavinas","year":"2011","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1810","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/dmd.105.008615","article-title":"In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates","volume":"34","author":"Rautio","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1815","doi-asserted-by":"crossref","first-page":"e0190629","DOI":"10.1371\/journal.pone.0190629","article-title":"A new fluorescent dye accumulation assay for parallel measurements of the ABCG2, ABCB1 and ABCC1 multidrug transporter functions","volume":"13","author":"Szabo","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1820","doi-asserted-by":"crossref","first-page":"G522","DOI":"10.1152\/ajpgi.2000.278.4.G522","article-title":"MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells","volume":"278","author":"Cantz","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"40","key":"10.1016\/j.bcp.2023.115448_b1825","doi-asserted-by":"crossref","first-page":"36923","DOI":"10.1074\/jbc.M105047200","article-title":"Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome","volume":"276","author":"Mor-Cohen","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1830","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1021\/acs.bioconjchem.5b00495","article-title":"Novel no-wash luminogenic probes for the detection of transporter uptake activity","volume":"27","author":"Mustafa","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1835","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/sj.bjp.0704284","article-title":"Role of multidrug resistance protein 2 (MRP2) in glutathione-bimane efflux from Caco-2 and rat renal proximal tubule cells","volume":"134","author":"Terlouw","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1840","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13318-018-0502-x","article-title":"Evaluation of drug biliary excretion using sandwich-cultured human hepatocytes","volume":"44","author":"Fardel","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1845","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1034\/j.1600-0676.2000.020004330.x","article-title":"Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis","volume":"20","author":"Milkiewicz","year":"2000","journal-title":"Liver"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1850","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/jps.22018","article-title":"Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes","volume":"99","author":"Ye","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1855","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1124\/jpet.115.225482","article-title":"The inhibitor Ko143 Is not specific for ABCG2","volume":"354","author":"Weidner","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1860","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1124\/dmd.108.024901","article-title":"Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and\/or ABCG2 inhibitors","volume":"37","author":"Oostendorp","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1865","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.cell.2015.07.022","article-title":"A call for systematic research on solute carriers","volume":"162","author":"Cesar-Razquin","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1870","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bbamem.2014.11.006","article-title":"Mutations of the central tyrosines of putative cholesterol recognition amino acid consensus (CRAC) sequences modify folding, activity, and sterol-sensing of the human ABCG2 multidrug transporter","volume":"1848","author":"Gal","year":"2015","journal-title":"BBA"},{"issue":"20","key":"10.1016\/j.bcp.2023.115448_b1875","doi-asserted-by":"crossref","first-page":"16667","DOI":"10.1074\/jbc.M010774200","article-title":"P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins","volume":"276","author":"Johnstone","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1880","doi-asserted-by":"crossref","first-page":"e0174905","DOI":"10.1371\/journal.pone.0174905","article-title":"Application of JC1 for non-toxic isolation of cells with MDR transporter activity by flow cytometry","volume":"12","author":"Wolosin","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b1885","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1208\/s12248-015-9752-6","article-title":"Molecular imaging of membrane transporters' activity in cancer: a picture is worth a thousand tubes","volume":"17","author":"Mann","year":"2015","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1890","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/17425255.2020.1718107","article-title":"Use of imaging to assess the activity of hepatic transporters","volume":"16","author":"Hernandez Lozano","year":"2020","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"issue":"19","key":"10.1016\/j.bcp.2023.115448_b1895","doi-asserted-by":"crossref","first-page":"9389","DOI":"10.1158\/0008-5472.CAN-07-0944","article-title":"ABCG2\/BCRP expression modulates D-Luciferin based bioluminescence imaging","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1900","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s11307-014-0741-4","article-title":"Oatp1 enhances bioluminescence by acting as a plasma membrane transporter for D-luciferin","volume":"16","author":"Patrick","year":"2014","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.bcp.2023.115448_b1905","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cbpa.2014.07.003","article-title":"Beyond D-luciferin: expanding the scope of bioluminescence imaging in vivo","volume":"21","author":"Adams","year":"2014","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115448_b1910","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.chembiol.2020.07.022","article-title":"Seeing (and using) the light: recent developments in bioluminescence technology","volume":"27","author":"Love","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1915","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.urolonc.2008.10.030","article-title":"In vivo optical imaging: preclinical applications and considerations","volume":"27","author":"Hickson","year":"2009","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1920","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00204-016-1906-5","article-title":"In vivo imaging of systemic transport and elimination of xenobiotics and endogenous molecules in mice","volume":"91","author":"Reif","year":"2017","journal-title":"Arch. Toxicol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1925","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/dmd.117.079277","article-title":"Intravital multiphoton microscopy with fluorescent bile salts in rats as an in vivo biomarker for hepatobiliary transport inhibition","volume":"46","author":"Ryan","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b1930","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jbio.200810058","article-title":"In vitro and in vivo imaging of xenobiotic transport in human skin and in the rat liver","volume":"1","author":"Roberts","year":"2008","journal-title":"J. Biophoton."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1935","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejps.2013.06.006","article-title":"Functional characterization of hepatic transporters using intravital microscopy","volume":"49","author":"Weiss","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1940","first-page":"1263","article-title":"Fluorescent bile acid derivatives: relationship between chemical structure and hepatic and intestinal transport in the rat","volume":"26","author":"Holzinger","year":"1997","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1945","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jps.21831","article-title":"Effects of P-glycoprotein and Mrp2 inhibitors on the hepatobiliary disposition of Rhodamine 123 and its glucuronidated metabolite in isolated perfused rat livers","volume":"99","author":"Parasrampuria","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1950","doi-asserted-by":"crossref","first-page":"121","DOI":"10.18433\/J33C7B","article-title":"Effects of long-term hepatic ischemia-reperfusion injury on the function of P-glycoprotein in vivo in rats","volume":"17","author":"Thorling","year":"2014","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b1955","doi-asserted-by":"crossref","first-page":"G1091","DOI":"10.1152\/ajpgi.90681.2008","article-title":"In vivo dynamic metabolic imaging of obstructive cholestasis in mice","volume":"296","author":"Li","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcp.2023.115448_b1960","doi-asserted-by":"crossref","unstructured":"M. Cardoso Dos Santos, I. Colin, G. Ribeiro Dos Santos, K. Susumu, M. Demarque, I.L. Medintz et al., Time-gated FRET nanoprobes for autofluorescence-free long-term in vivo imaging of developing zebrafish, Adv Mater. 32(39) (2020) e2003912.","DOI":"10.1002\/adma.202003912"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b1965","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41377-021-00628-0","article-title":"Perfecting and extending the near-infrared imaging window","volume":"10","author":"Feng","year":"2021","journal-title":"Light Sci. Appl."},{"key":"10.1016\/j.bcp.2023.115448_b1970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41551-016-0010","article-title":"Near-infrared fluorophores for biomedical imaging","volume":"1","author":"Hong","year":"2017","journal-title":"Nat. Biomed. Eng."},{"issue":"34","key":"10.1016\/j.bcp.2023.115448_b1975","doi-asserted-by":"crossref","first-page":"56880","DOI":"10.18632\/oncotarget.18131","article-title":"Heptamethine carbocyanine DZ-1 dye for near-infrared fluorescence imaging of hepatocellular carcinoma","volume":"8","author":"An","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b1980","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1096\/fj.201700767R","article-title":"Organic anion-transporting polypeptide 1B3 as a dual reporter gene for fluorescence and magnetic resonance imaging","volume":"32","author":"Wu","year":"2018","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b1985","doi-asserted-by":"crossref","first-page":"e190035","DOI":"10.1148\/rycan.2019190035","article-title":"Development of a human photoacoustic imaging reporter gene using the clinical dye indocyanine green","volume":"1","author":"Nystrom","year":"2019","journal-title":"Radiol Imag. Cancer."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b1990","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1021\/acs.molpharmaceut.5b00374","article-title":"Near infrared imaging of indocyanine green distribution in pregnant mice and effects of concomitant medications","volume":"12","author":"Bishara","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2023.115448_b1995","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fphar.2016.00426","article-title":"Evaluation of near infrared dyes as markers of p-glycoprotein activity in tumors","volume":"7","author":"Semenenko","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2000","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.surg.2009.12.004","article-title":"Real-time intra-operative near-infrared fluorescence identification of the extrahepatic bile ducts using clinically available contrast agents","volume":"148","author":"Matsui","year":"2010","journal-title":"Surgery"},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b2005","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1124\/dmd.118.083584","article-title":"Pheophorbide a: fluorescent bcrp substrate to measure oral drug-drug interactions in real-time in vivo","volume":"46","author":"Yasuda","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b2010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nucmedbio.2015.12.001","article-title":"(67\/68)Galmydar: a metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity","volume":"43","author":"Sivapackiam","year":"2016","journal-title":"Nucl. Med. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b2015","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/1078-0432.CCR-10-0059","article-title":"Near IR heptamethine cyanine dye-mediated cancer imaging","volume":"16","author":"Yang","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"28","key":"10.1016\/j.bcp.2023.115448_b2020","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1016\/j.biomaterials.2014.05.073","article-title":"Near-infrared fluorescence imaging of cancer mediated by tumor hypoxia and HIF1alpha\/OATPs signaling axis","volume":"35","author":"Wu","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2023.115448_b2025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.654921","article-title":"The use of heptamethine cyanine dyes as drug-conjugate systems in the treatment of primary and metastatic brain tumors","volume":"11","author":"Cooper","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b2030","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1021\/acs.accounts.0c00733","article-title":"Hows and whys of tumor-seeking dyes","volume":"54","author":"Usama","year":"2021","journal-title":"Acc. Chem. Res."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b2035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1021\/acs.bioconjchem.9b00771","article-title":"Role of albumin in accumulation and persistence of tumor-seeking cyanine dyes","volume":"31","author":"Usama","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bcp.2023.115448_b2040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.930065","article-title":"Indocyanine green fluorescence-guided laparoscopic hepatectomy versus conventional laparoscopic hepatectomy for hepatocellular carcinoma: a single-center propensity score matching study","volume":"12","author":"Jianxi","year":"2022","journal-title":"Front. Oncol."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2023.115448_b2045","first-page":"54","article-title":"Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep","volume":"1738","author":"Hayashi","year":"2005","journal-title":"BBA"},{"issue":"33","key":"10.1016\/j.bcp.2023.115448_b2050","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.2174\/0929867326666190627123719","article-title":"The role of NIR fluorescence in mdr cancer treatment: from targeted imaging to phototherapy","volume":"27","author":"Wang","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b2055","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.biomaterials.2013.10.033","article-title":"Mechanistic study of IR-780 dye as a potential tumor targeting and drug delivery agent","volume":"35","author":"Zhang","year":"2014","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b2060","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1021\/acsabm.8b00414","article-title":"Optimized heptamethine cyanines for photodynamic therapy","volume":"1","author":"Usama","year":"2018","journal-title":"ACS Appl Bio Mater."},{"key":"10.1016\/j.bcp.2023.115448_b2065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105758","article-title":"Indomethacin-based near-infrared photosensitizer for targeted photodynamic cancer therapy","volume":"122","author":"Siriwibool","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bcp.2023.115448_b2070","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.09.003","article-title":"Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development","volume":"37","author":"Mochizuki","year":"2021","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b2075","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the international transporter consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b2080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.vascn.2012.02.002","article-title":"Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers","volume":"65","author":"Melchior","year":"2012","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b2085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1124\/jpet.119.261347","article-title":"Direct measurement of kinetic parameters of ABCG2-dependent transport of natural flavonoids using a fluorogenic substrate","volume":"371","author":"Rozanski","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b2090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-007-0219-x","article-title":"Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1)","volume":"376","author":"Nies","year":"2008","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115448_b2095","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1021\/jacs.1c08485","article-title":"Molecular imaging of labile heme in living cells using a small molecule fluorescent probe","volume":"144","author":"Kawai","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2023.115448_b2100","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1039\/C7AY01708A","article-title":"Fluorescent sensors for sodium ions","volume":"9","author":"Gao","year":"2017","journal-title":"Anal Meth."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b2105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1124\/mol.58.2.335","article-title":"Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione","volume":"58","author":"Li","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b2110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1054\/bjoc.2000.1262","article-title":"Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export","volume":"83","author":"Evers","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2023.115448_b2115","unstructured":"T. Riss, A. Niles, R. Moravec, N. Karassina, J. Vidugiriene, Cytotoxicity assays: in vitro methods to measure dead cells. In: S. Markossian, A. Grossman, K. Brimacombe, M. Arkin, D. Auld, C. Austin et al. (Eds.), Assay Guidance Manual. Bethesda (MD), 2004."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b2120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/adt.2008.165","article-title":"A dual-fluorescence high-throughput cell line system for probing multidrug resistance","volume":"7","author":"Brimacombe","year":"2009","journal-title":"Assay Drug Dev. Technol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2125","first-page":"1","article-title":"Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer\/oligomer formation of the human breast cancer resistance protein (BCRP\/ABCG2) in intact cells","volume":"1","author":"Ni","year":"2010","journal-title":"Int. J. Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b2130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jphotobiol.2007.03.001","article-title":"Energy transfer to analyse membrane-integrated mitoxantrone in BCRP-overexpressed cells","volume":"87","author":"Breuzard","year":"2007","journal-title":"J. Photochem. Photobiol. B"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b2135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183218","article-title":"Application of fluorescence correlation spectroscopy to study substrate binding in styrene maleic acid lipid copolymer encapsulated ABCG2","volume":"1862","author":"Horsey","year":"2020","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b2140","doi-asserted-by":"crossref","first-page":"e25818","DOI":"10.1371\/journal.pone.0025818","article-title":"Dimerization of ABCG2 analysed by bimolecular fluorescence complementation","volume":"6","author":"Haider","year":"2011","journal-title":"PLoS One"},{"issue":"6141","key":"10.1016\/j.bcp.2023.115448_b2145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b2150","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1021\/acschembio.8b00270","article-title":"Detection of chemical engagement of solute carrier proteins by a cellular thermal shift assay","volume":"13","author":"Hashimoto","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115448_b2155","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1038\/s41596-021-00619-w","article-title":"The GFP thermal shift assay for screening ligand and lipid interactions to solute carrier transporters","volume":"16","author":"Chatzikyriakidou","year":"2021","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b2160","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/hep.23083","article-title":"De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis","volume":"50","author":"Keitel","year":"2009","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b2165","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1021\/acs.molpharmaceut.1c00939","article-title":"Noninvasive evaluation of multidrug resistance via imaging of ABCG2\/BCRP multidrug transporter in lung cancer xenograft models","volume":"19","author":"Li","year":"2022","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.bcp.2023.115448_b2170","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1021\/acs.molpharmaceut.7b00420","article-title":"Molecular imaging of P-glycoprotein in chemoresistant tumors using a dual-modality PET\/fluorescence probe","volume":"14","author":"Wang","year":"2017","journal-title":"Mol. Pharm."},{"issue":"37","key":"10.1016\/j.bcp.2023.115448_b2175","doi-asserted-by":"crossref","first-page":"31561","DOI":"10.1074\/jbc.M112.388793","article-title":"A substrate binding hinge domain is critical for transport-related structural changes of organic cation transporter 1","volume":"287","author":"Egenberger","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b2180","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41594-018-0049-1","article-title":"Structural basis of small-molecule inhibition of human multidrug transporter ABCG2","volume":"25","author":"Jackson","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.62.1.1","article-title":"Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system","volume":"62","author":"Kimchi-Sarfaty","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b2190","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/bc500154c","article-title":"In vivo imaging of multidrug resistance using a third generation MDR1 inhibitor","volume":"25","author":"Sprachman","year":"2014","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b2195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002320001020","article-title":"Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system","volume":"173","author":"Gribar","year":"2000","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.bcp.2023.115448_b2200","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0076-6879(98)92035-3","article-title":"Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system","volume":"292","author":"Hrycyna","year":"1998","journal-title":"Methods Enzymol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2205","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(91)90141-K","article-title":"Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells","volume":"66","author":"Chaudhary","year":"1991","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b2210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.leukres.2006.07.016","article-title":"Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice","volume":"31","author":"Vasconcelos","year":"2007","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b2215","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/sj.leu.2400698","article-title":"Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe","volume":"11","author":"Kuhnel","year":"1997","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1432-1327.1998.2540181.x","article-title":"Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein","volume":"254","author":"Shapiro","year":"1998","journal-title":"Eur. J. Biochem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b2225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/B:BIRE.0000007693.33521.18","article-title":"Mitotracker green is a P-glycoprotein substrate","volume":"23","author":"Marques-Santos","year":"2003","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2230","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bcp.2010.03.010","article-title":"Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy","volume":"80","author":"Patwardhan","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115448_b2235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejps.2015.03.026","article-title":"2'[(18)F]-fluoroethylrhodamine B is a promising radiotracer to measure P-glycoprotein function","volume":"74","author":"Trencsenyi","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2240","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1432-1033.1997.00104.x","article-title":"Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate","volume":"248","author":"Eytan","year":"1997","journal-title":"Eur. J. Biochem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b2245","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.23387","article-title":"Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1","volume":"88","author":"Hawley","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b2250","first-page":"2173","article-title":"Demonstration of the activity of P-glycoprotein by a semi-automated fluorometric method","volume":"29","author":"Spengler","year":"2009","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b2255","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.celrep.2014.02.006","article-title":"A chemical probe that labels human pluripotent stem cells","volume":"6","author":"Hirata","year":"2014","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.bcp.2023.115448_b2260","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1124\/dmd.105.005314","article-title":"Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2)","volume":"33","author":"Lindenmaier","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.bcp.2023.115448_b2265","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/dmd.116.074740","article-title":"Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay","volume":"45","author":"Gilibili","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2023.115448_b2270","article-title":"Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans","volume":"2011","author":"Benz-de Bretagne","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b2275","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/mp2001022","article-title":"Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters","volume":"8","author":"Shukla","year":"2011","journal-title":"Mol. Pharm."},{"issue":"22","key":"10.1016\/j.bcp.2023.115448_b2280","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/cbic.201600490","article-title":"A Fluorescent probe for neural stem\/progenitor cells with high differentiation capability into neurons","volume":"17","author":"Kim","year":"2016","journal-title":"Chembiochem"},{"issue":"4","key":"10.1016\/j.bcp.2023.115448_b2285","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.biomaterials.2012.10.059","article-title":"The use of fluorescent indoline dyes for side population analysis","volume":"34","author":"Kohara","year":"2013","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2290","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/mol.106.023556","article-title":"Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport","volume":"70","author":"Tamura","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115448_b2295","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/00498254.2015.1085111","article-title":"Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III","volume":"46","author":"Bednarczyk","year":"2016","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.bcp.2023.115448_b2300","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.116.234914","article-title":"Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition","volume":"358","author":"Lai","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2023.115448_b2305","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/tpj.2010.75","article-title":"Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron","volume":"12","author":"Tzvetkov","year":"2012","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"10.1016\/j.bcp.2023.115448_b2310","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.bcp.2008.07.005","article-title":"Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1\/hMATE1 and hOCT2\/hMATE1","volume":"76","author":"Sato","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115448_b2315","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.molpharmaceut.5b00733","article-title":"The Nonmetabolized beta-blocker nadolol is a substrate of OCT1, OCT2, MATE1, MATE2-K, and P-glycoprotein, but Not of OATP1B1 and OATP1B3","volume":"13","author":"Misaka","year":"2016","journal-title":"Mol. Pharm."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:15:45Z","timestamp":1762096545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":463,"alternative-id":["S0006295223000394"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115448","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluorescence-based methods for studying activity and drug-drug interactions of hepatic solute carrier and ATP binding cassette proteins involved in ADME-Tox","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115448"}}